The latest from
Multiply Labs.

Multiply Labs announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration will focus on end-to-end robotic automation of industry-standard instruments, with the goal of enabling scalable, high-throughput manufacturing while meeting rigorous clinical and commercial quality standards.

Multiply Labs announced a collaboration with NVIDIA to bring Physical AI robotics technology to advanced biomanufacturing. The partnership will leverage NVIDIA's AI computing platform to enhance robotic automation for cell therapy manufacturing.

Multiply Labs announced an expansion of its collaboration with Thermo Fisher Scientific to integrate robotic automation with the Gibco™ CTS™ DynaCellect™ Magnetic Separation System. The partnership aims to enable scalable and efficient end-to-end manufacturing processes to meet growing demand for cell therapies.

Multiply Labs announced a pilot collaboration with Kyverna Therapeutics to automate cell therapy manufacturing using robotic systems. The partnership will evaluate automation of Kyverna's manufacturing processes for KYV-102, incorporating its patented fully human CD19 CAR-T and proprietary whole-blood rapid manufacturing approach.

Multiply Labs and Legend Biotech—known for the J&J-partnered CAR-T therapy Carvykti—have announced a collaboration to automate cell therapy production through robotics. As part of the deal, Legend Biotech will receive priority access to Multiply Labs' automated systems.

Multiply Labs is establishing a collaboration with Stanford GMP Facility: Laboratory for Cell and Gene Medicine (LCGM) to deploy robotic systems for cell therapy manufacturing. The partnership combines LCGM's unmatched process development expertise with Multiply's robotic technology to enable cell therapy organizations to compare manual and automated processes side-by-side.

WuXi STA and Multiply Labs announced a partnership to deploy robotic manufacturing technology for personalized medications. Personalized doses can now be filled into single- or multi-compartment capsules for GMP manufacturing, enabling the production of individualized drug formulations previously challenging to manufacture at scale.

Thermo Fisher Scientific and Charles River Laboratories have joined Multiply Labs' consortium to automate cell therapy manufacturing. The expanded partnership broadens the ecosystem of instrument partners working to make robotic biomanufacturing commercially viable at scale.

Fierce Pharma covers the expansion of Multiply Labs' consortium with Thermo Fisher Scientific and Charles River Laboratories, highlighting the growing industry momentum behind robotic automation for cell therapy manufacturing.

MIT Technology Review explores how Multiply Labs' robotic clusters could ease major bottlenecks in the production of drugs for intractable diseases, examining the technology's potential to transform cell and gene therapy manufacturing.

Cytiva and Multiply Labs announced a collaboration to automate cell therapy manufacturing, combining Cytiva's bioprocess technologies with Multiply Labs' robotic cluster platform to streamline production workflows.